Summary
Sulfasalazine (Salazopyrin®) was launched in France en 1958. Its current indications are: ulcerative colitis, colic Crohn’s disease and rheumatoid arthritis. This molecule has few uses in a dermatological setting.
×
N.B. : This limited content is for the general public. If you are a health professional, click here to register for free and gain access to a dedicated deeper content.
If you already have an account, log in!
Therapeutics in Dermatology, Fondation René Touraine © 2001-2012
